- Home
- BCDA vs SPHL Comparison
BCDA vs SPHL Comparison
Compare BCDA & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- SPHL
- Stock Information
- Founded
- BCDA N/A
- SPHL 2002
- Country
- BCDA United States
- SPHL Singapore
- Employees
- BCDA 17
- SPHL N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- SPHL Homebuilding
- Sector
- BCDA Health Care
- SPHL Consumer Discretionary
- Exchange
- BCDA Nasdaq
- SPHL Nasdaq
- Market Cap
- BCDA 13.7M
- SPHL 11.4M
- IPO Year
- BCDA N/A
- SPHL 2024
- Fundamental
- Price
- BCDA $1.32
- SPHL $0.42
- Analyst Decision
- BCDA Strong Buy
- SPHL
- Analyst Count
- BCDA 1
- SPHL 0
- Target Price
- BCDA $25.00
- SPHL N/A
- AVG Volume (30 Days)
- BCDA 125.5K
- SPHL 1.5M
- Earning Date
- BCDA 11-12-2025
- SPHL 12-29-2025
- Dividend Yield
- BCDA N/A
- SPHL N/A
- EPS Growth
- BCDA N/A
- SPHL N/A
- EPS
- BCDA N/A
- SPHL N/A
- Revenue
- BCDA N/A
- SPHL $5,956,226.00
- Revenue This Year
- BCDA N/A
- SPHL N/A
- Revenue Next Year
- BCDA N/A
- SPHL N/A
- P/E Ratio
- BCDA N/A
- SPHL N/A
- Revenue Growth
- BCDA N/A
- SPHL N/A
- 52 Week Low
- BCDA $1.00
- SPHL $0.35
- 52 Week High
- BCDA $3.20
- SPHL $7.80
- Technical
- Relative Strength Index (RSI)
- BCDA 43.26
- SPHL 40.08
- Support Level
- BCDA $1.25
- SPHL $0.42
- Resistance Level
- BCDA $1.45
- SPHL $0.83
- Average True Range (ATR)
- BCDA 0.08
- SPHL 0.13
- MACD
- BCDA 0.00
- SPHL -0.02
- Stochastic Oscillator
- BCDA 27.00
- SPHL 10.78
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.